INTRODUCTION
Ljungan virus (LV; currently also known as Parechovirus B; genus Parechovirus, family Picornaviridae) [Reference Niklasson1, Reference Knowles, King, Adams, Carstens and Lefkowitz2] is considered a rodent-borne virus, since it has thus far been isolated from the bank vole (Myodes glareolus) in Europe [Reference Niklasson1] and two other vole species of subfamily Arvicolinae in North America [Reference Tolf3–Reference Johansson5]. LV RNA has been detected in several rodent species of the Muridae family [Reference Niklasson6–Reference Salisbury9]. Besides LV, the genus Parechovirus includes the human parechoviruses (HPeVs) consisting of 16 currently known genotypes [Reference Knowles, King, Adams, Carstens and Lefkowitz2]. Several HPeV types are highly prevalent in humans and more than 90% of adults have had HPeV infection [Reference Harvala10, Reference Westerhuis11]. Some HPeVs have also been detected in non-human primates and swine [Reference Shan12–Reference Oberste14]. Interestingly, HPeV4 strains detected in humans and swine in Bolivia [Reference Nix13] lacked an RGD motif found in VP1 carboxyl-termini of all other HPeV4s, and had instead a variant carboxyl-terminal end (17 amino acids). This finding resembles characteristics of LV, as the RGD motif is lacking and LV has a variant carboxyl-terminal end (43 amino acids long) [Reference Joffret15]. Recently, two new species of Parechovirus, the Sebokele virus 1 isolated from the African wood mouse (Hylomyscus sp.) [Reference Smits16], and the ferret parechovirus [Reference Johansson17] have been suggested.
LV infection has been suggested to be involved in intrauterine death [Reference Samsioe18], central nervous system (CNS) malformations [Reference Niklasson19], sudden infant death syndrome [Reference Niklasson20] and type 1 diabetes [Reference Niklasson21, Reference Nilsson22], but the associations remain unconfirmed. Thus far, as for virological data seroepidemiological data on LV infections in humans are also scarce: the existing two studies were restricted to children and adolescents in Southern Sweden [Reference Niklasson21, Reference Nilsson22]. In our earlier study, we established and evaluated LV-specific immunofluorescence and neutralization assays, and in a small panel of Finnish human sera detected a surprisingly high prevalence (38%) of neutralizing antibodies to LV [Reference Jääskeläinen23].
In this study, we aimed to characterize the demographic and geographical variation in the prevalence of LV-reactive antibodies in the Finnish human population. The Finnish population provides an optimal landscape for seroepidemiological studies on LV, since the incidence of another bank vole-borne virus, Puumala hantavirus (PUUV) causing nephropathia epidemica (NE) in humans is highest in Finland among the European Union countries [Reference Vaheri24]. For this reason, the epidemiology of NE is well known in Finland [Reference Brummer-Korvenkontio25–Reference Vapalahti27]. We hypothesized that if LV was transmitted from bank voles to humans, the seroepidemiological characteristics of LV would resemble those of PUUV, and furthermore, expected to find a positive association between earlier exposure to bank vole excreta (as indicated by the presence of PUUV antibodies) and the presence of LV-reactive antibodies.
METHODS
Altogether, we selected 1378 serum samples, representing 17 of the 20 Finnish hospital districts for the study (Table 1). The sera were acquired from archived sample panels of the Department of Virology and Immunology, Helsinki University Central Hospital, collected during 2006–2014. Most samples (n = 1155) were acquired without any prior selection from a panel of patients with suspected acute NE and tested for PUUV IgG and/or IgM antibodies. However, children, adolescents and women were underrepresented in this panel, and therefore the dataset was supplemented with two other groups: sera from pregnant women (n = 88) and patients aged <20 years (n = 135) with suspected acute CNS infection. The sera from pregnant women had been previously tested for syphilis and antibodies against hepatitis B and HIV, and the sera from CNS patients tested for antibodies to herpes simplex viruses (HSV) -1 and -2, varicella-zoster virus (VZV), human herpesvirus-6 (HHV-6), Mycoplasma pneumoniae, influenza viruses A and B, parainfluenza viruses, enteroviruses, and adenoviruses.
Table 1. Numbers tested (percent positive in parentheses) by Ljungan virus immunofluorescence assay
NE, Nephropathia epidemica; CNS, central nervous system; PUUV, Puumala virus.
The sera were diluted in 1:20 phosphate-buffered saline and tested for the presence of LV-reactive IgG antibodies using an immunofluorescence assay (IFA) (LV strain 145SLG) described previously [Reference Jääskeläinen23].
The distribution of the studied samples was not equal across different sexes, age groups, hospital districts, and patient groups (Table 1), so that the effects these factors on the likelihood on LV antibody positivity were likely to confound each other. As such, we used a multivariable analysis for statistical inference. Since the effect of age on the likelihood of LV-IFA positivity was not expected to follow any particular pattern, we used generalized additive models (GAMs), where age was included as a smooth term and sex, hospital district and patient group were included as factors. Using a similar model, we further studied whether a history of exposure to bank vole excreta (as indicated by the presence of PUUV antibodies) increased the likelihood of being positive for LV IgG antibodies by IFA. In this analysis, only data from patients suspected of having NE and of known PUUV antibody status (i.e. tested for both IgM and IgG antibodies n = 1129) were used. The presence of either PUUV IgM, IgG, or both was interpreted as PUUV antibody positivity and therefore, an earlier exposure to bank vole excreta was assumed. In addition to age-smooth term, sex and hospital district, PUUV antibody status was included as an explanatory factor. Binomial error distributions and a logit link function were used in both analyses. The analyses were run with R statistical software [28] using the ‘gam’ function of the gamm4 package [Reference Wood29]. Statistical inference was made from the full models to avoid any confounding effects between explanatory variables. Pregnant women were considered to represent a healthy background population, and therefore the group was selected as the baseline level for model predictions.
RESULTS
In total, we found 36% (497/1378) of sera to be positive by LV-IFA. The observed group-wise seroprevalences (by age group, sex, hospital district, patient group) are reported in Table 1. Individual age had a statistically significant effect on the probability of being LV-IFA positive (Table 2). In the analysis of the entire dataset, the predicted likelihood of LV-IFA positivity increased from 33% [95% confidence interval (CI) 12–55] in infants (<1 year) to 60% (95% CI 45–75) by age 14 years (Fig. 1). Thereafter the likelihood decreased steadily, being 22% (95% CI 0–48) at age 96 years. Males were significantly more often seropositive than females (Table 2); according to the predictions from the entire dataset model, 48% (95% CI 33–63) of average-aged men (46 years) and 40% (95% CI 27–53) of women were likely to be LV seropositive.
Fig. 1. Ljungan virus-reactive antibodies (LV-Ab) in relation to age in Helsinki & Uusimaa and Central Finland hospital districts. The lines represent the probabilities predicted by the generalized additive model and the grey areas indicate 95% confidence intervals for predicted values, the shading being darker where intervals overlap. The values are calculated for a female representing a healthy background population (pregnant women). The dots represent the observed proportions in each age group and vertical bars indicate their 95% confidence intervals.
Table 2. Parameter coefficients (on logit scale) of generalized additive models analysing the probability of being Ljungan virus-immunofluorescence assay positive for the entire dataset and for NE suspects data
NE, Nephropathia epidemica; s.e., standard error of parameter estimate; z, model test statistic; PUUV, Puumala hantavirus; CNS, central nervous system.
* The intercept represents an average-aged female from Helsinki & Uusimaa hospital district, a healthy background population (pregnant women's group; ‘entire data set’ model) and a PUUV antibody negative patient (‘NE suspects’ model).
† The smooth terms of age had 6·4 and 1 estimated degrees of freedom in the ‘entire dataset’ and ‘NE suspects’ models, respectively.
The prevalence of LV-reactive antibodies was significantly lower in the hospital district of Central Finland than in the Helsinki & Uusimaa district (Table 1, Fig. 1); the predicted probability for an average-aged woman of the background population to be LV-seropositive in Central Finland was 25% (95% CI 13–38), and in Helsinki & Uusimaa it was 40% (95% CI 27–53). Compared to the healthy background population (pregnant women), patients suspected of having NE or an acute CNS infection had no significantly different probabilities of being positive by LV-IFA (Table 2). In the CNS panel, 21/115 patients had clinically significant findings: 10 were considered to have acute or recently acquired M. pneumoniae infection, four had reactivated HHV-6, one acute HHV-6 infection, four VZV infections, one acute HSV-2 infection, and one enterovirus infection (Table 3). Six out of 10 M. pneumoniae cases were LV seropositive, 4/5 HHV-6 cases, 2/4 VZV cases and the only HSV-2 case was positive for LV IgG. The acute enterovirus infection was negative for LV IgG (Table 3).
Table 3. Significant microbial findings of patients with suspected CNS infection
LV, Ljungan virus; ICU, intensive care unit; HHV-6, human herpesvirus 6; VZV, varicella-zoster virus; HSV-2, herpes simplex virus 2; EV, enterovirus; CNS, central nervous system; CSF, cerebrospinal fluid.
In the model for suspected NE patients alone, the presence of PUUV antibodies was not significantly associated with LV-reactive antibodies (Table 2). Of suspected NE cases, as in the entire dataset, males were more likely to be LV-IFA positive than females, and the prevalence of LV-reactive antibodies was lower in Central Finland than in the Helsinki & Uusimaa hospital district (Table 1). When analysing only NE suspected patients, the likelihood of positivity decreased linearly by age, in contrast to the pattern seen in Fig. 1. for the entire dataset. Significant microbial findings among patients with CNS symptoms and their co-occurrence with LV-reactive antibodies are reported in Table 3.
DISCUSSION
The high overall prevalence (36%) of LV-reactive antibodies in a population of 1378 Finns corroborated the results of our earlier pilot study done in conjunction by establishing and evaluating the LV antibody tests, where 14/37 Finns (38%) were found positive for LV antibodies in both IFA and neutralization tests [Reference Jääskeläinen23]. Here we found the probability of possessing LV-reactive antibodies to be positively associated with male sex and living in the Helsinki & Uusimaa district, the most urbanized area in Finland, and to peak in adolescents aged 14 years, declining thereafter. The analysis of suspected NE cases alone did not show a similar increase of antibody prevalence before adolescence, but this was probably due to a low number (n = 24) of NE suspects aged <14 years. The presence of LV-reactive antibodies was neither associated with being suspected of or having contracted NE, or being suspected of having a CNS infection.
Overall, our findings on LV-reactive antibodies markedly differ from the epidemiological characteristics of PUUV, the causative agent of NE. First, we found the prevalence of LV-reactive antibodies to peak at adolescence, implying that most infections/contacts take place in childhood. By contrast, the risk for contracting NE is highest between ages 37 and 59 years [Reference Vapalahti27] and the prevalence of PUUV antibodies increases until old age [Reference Brummer-Korvenkontio25]. We also observed a decline in the prevalence of LV-reactive antibodies from adolescence to old age, which could be due to waning immunity against the virus in question. However, it seems unlikely that contacts with such a prevalent virus would become notably scarcer with increasing age. Second, our observations of the geographical distribution of LV-reactive antibodies contrast with those of NE. We found LV-reactive antibodies to be significantly more prevalent in Helsinki & Uusimaa than in Central Finland, where NE incidence is nearly six times higher than in Helsinki & Uusimaa [Reference Makary26]. The geographical distribution of NE incidence is considered to reflect the differences in contact rate between bank voles and humans: Helsinki & Uusimaa district is more urbanized, less forested, and has less prominent bank vole population fluctuations than the central and northern parts of the country [Reference Hansson and Henttonen30]. Therefore, a similar distribution in human incidence could be anticipated for any bank vole-borne pathogen, including LV. Third, we found LV-reactive antibodies to be much more prevalent in the human population than PUUV antibodies: in the Finnish human population, the overall seroprevalence of PUUV antibodies has been estimated to be 5% [Reference Brummer-Korvenkontio25]. By contrast, in bank voles, LV antibodies have been reported to be somewhat less prevalent (18%) [Reference Jääskeläinen23] than PUUV antibodies (20–25%) [Reference Kallio31, Reference Razzauti32] in the same vole population and time period in autumn. The only result in line with the reported epidemiological associations of NE was the higher antibody prevalence in males [Reference Brummer-Korvenkontio25]. However, male-biased infection is common for pathogens of humans [Reference Guerra-Silveira and Abad-Franch33] and other vertebrates [Reference Zuk and McKean34], and is thought to be mediated by physiological and/or behavioural differences between sexes.
These points, together with our finding that LV-reactive antibodies were not more common among suspected NE patients who had been exposed to bank vole excreta (indicated by the presence of PUUV antibodies) compared to those without any knowledge of exposure, lead us to two scenarios that are not necessarily mutually exclusive: (i) LV is not host-specific to bank voles or to rodents generally, but also circulates among humans, or/and (ii) the antibodies observed in this study are not solely, or at all, caused by the currently known LV, but by one or several antigenically similar viruses. The first scenario, i.e. host promiscuity of LV, seems less plausible: although LV RNA has been detected in several rodent species, and HPeVs, the human-borne closest relatives of LV may cross species or even mammalian order boundaries [Reference Shan12–Reference Oberste14], we consider it rather unlikely that a rodent-borne LV could circulate in humans effectively enough as to reach the high seroprevalence observed here.
Indeed, the scenario that the observed antibody responses are due to an infection by another, antigenically related to LV, seems more likely. Although HPeVs are highly prevalent in the Finnish population [Reference Westerhuis11, Reference Tauriainen35], we do not consider cross-reactions to currently known HPeVs to be a likely cause of the observed LV-reactive antibodies, since antibodies against the five most prevalent HPeV types in Finland (HPeV 1, 2, 4–6) [Reference Westerhuis11], did not cross-react with LV [Reference Jääskeläinen23]. The recent discoveries of new parechoviruses in rodents [Reference Joffret15], and mustelids [Reference Smits16], Ljungan-like sequences in swine [Reference Yu36] and non-human primates [Reference Oberste14], as well as the continuously widening array of HPeV types also found in non-humans [Reference Shan12–Reference Oberste14, Reference Oberste37], imply that the host spectrum and genetic diversity of parechoviruses may be much wider than initially thought. Therefore we consider it likely that most, if not all, of the antibody responses observed here were induced by one or several thus far unknown Ljungan-like viruses that circulate in humans.
Whatever the causative agent of the LV-reactive antibodies observed in this study was, its disease association is probably minor: for the seroconversion to reach 60% in 14-year-old adolescents, more than 2700 infections would need to take place yearly in Finnish children aged 0–14 years. However, closely related HPeVs are known to cause severe infections in infants [Reference Harvala10, Reference Jääskeläinen38, Reference Kolehmainen39] and therefore, investigations are warranted to identify the causative agent(s) of antibodies observed here and to search for its/their possible disease associations.
It cannot be ruled out that a proportion of the antibodies observed in this study are due to actual LV infections. But as we cannot conclude how large this proportion is, any conclusions about the disease associations of LV cannot be drawn on the basis of this study.
To conclude, we believe that one or several Ljungan-like viruses, with probably minor disease associations, are circulating in the Finnish human population. However, as closely related HPeVs may cause serious infections in children, investigations to identify these unknown agents are warranted. In near future, next-generation sequencing methods and broad-spectrum PCRs will hopefully shed more light on the host spectrum, genetic diversity and pathogenic potential of Ljungan and related viruses.
ACKNOWLEDGEMENTS
We thank Mira Utriainen and Markku Lehtinen for excellent technical assistance. The study was financially supported by HUSLAB (grant no. TYH2011305; Helsinki University Hospital, Finland), Kone Foundation and EU grant FP7-261504 EDENext and is catalogued by the EDENext Steering Committee as EDENext314 (http://www.edenext.eu). The contents of this publication are the sole responsibility of the authors and do not necessarily reflect the views of the European Commission.
DECLARATION OF INTEREST
None.
